Quercetin activates the Sestrin2/AMPK/SIRT1 axis to improve amyotrophic lateral sclerosis - 28/03/23

Abstract |
Amyotrophic lateral sclerosis (ALS) is a chronic neurodegenerative disease with poor prognosis. The intricacies surrounding its pathophysiology could partly account for the lack of effective treatment for ALS. Sestrin2 has been reported to improve metabolic, cardiovascular and neurodegenerative diseases, and is involved in the direct and indirect activation of the adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK)/silent information regulator 1 (SIRT1) axis. Quercetin, as a phytochemical, has considerable biological activities, such as anti-oxidation, anti-inflammation, anti-tumorigenicity, and neuroprotection. Interestingly, quercetin can activate the AMPK/SIRT1 signaling pathway to reduce endoplasmic reticulum stress, and alleviate apoptosis and inflammation. This report examines the molecular relationship between Sestrin2 and AMPK/SIRT1 axis, as well as the main biological functions and research progress of quercetin, together with the correlation between quercetin and Sestrin2/AMPK/SIRT1 axis in neurodegenerative diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | We provide an overview of proposed molecular mechanisms of amyotrophic lateral sclerosis and their connections to neurodegenerative diseases. |
• | We summarize the most relevant study of amyotrophic lateral sclerosis and quercetin. |
• | We review the main biological functions of quercetin, together with the correlation between quercetin and Sestrin2/AMPK/SIRT1 axis in neurodegenerative diseases. |
Abbreviation : ALS, AMP, AMPK, SIRT1, SOD1, ROS, LDL, CaMKKβ, LKB1, SIRT, FOXO, P53, Nrf2, NAMPT, SOD, CAT, NAD, NADH, mTOR, HO-1, MAPK, NF-kB
Keywords : Sestrin2, Adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK), Silent information regulator 1 (SIRT1), Amyotrophic lateral sclerosis, Neurodegenerative diseases
Plan
Vol 161
Article 114515- mai 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?